Stephenson Harwood advises capiton on KD Pharma single-asset secondary

KD Pharma Group is a producer of omega-3 ingredients for pharmaceutical and nutraceutical products. It was acquired by capiton IV fund in 2013 and has grown from a single-digit revenue business to one of the industry’s largest players. 

capiton initiated a GP-led single-asset secondary transaction to provide KD Pharma with the necessary duration and follow-on capital to finance the Group’s future growth potential. The oversubscribed transaction enabled capiton to successfully close the fundraising for its new single-asset continuation fund and gave existing partners an early liquidity option to either sell their stake or to remain (partially or fully) invested in KD Pharma. Under the new fund structure capiton will continue to manage its portfolio company KD Pharma for further growth as general partner. 

The Stephenson Harwood team was led by partner Gabriel Boghossian with support from associates Victoria Silver and Marina Pappas. The team co-advised capiton alongside CMS Hasche Sigle and P+P Pöllath + Partners. The financial advisor was PJT Park Hill.